AHS 2018

The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.

Eptinezumab has shown 100% bioavailability when administered intravenously.

Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.

Results from the ACHIEVE II study were presented at the American Headache Society’s 60th Annual Scientific Meeting.

In the post-hoc analysis, researchers evaluated the time to onset of effect of galcanezumab as well as whether treatment with the study drug was associated with a reduction in migraine headache days.

Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.

Individuals with chronic migraine may present with age-related changes in cortical thickness.

The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.

The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.

In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.